Rice Hall James & Associates LLC Raises Stake in OmniAb, Inc. (NASDAQ:OABI)

Rice Hall James & Associates LLC grew its stake in shares of OmniAb, Inc. (NASDAQ:OABI - Free Report) by 6.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,722,321 shares of the company's stock after acquiring an additional 163,038 shares during the quarter. Rice Hall James & Associates LLC owned about 2.31% of OmniAb worth $11,515,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Towerview LLC increased its position in OmniAb by 114.0% during the second quarter. Towerview LLC now owns 535,000 shares of the company's stock valued at $2,006,000 after acquiring an additional 285,000 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company's stock worth $11,296,000 after purchasing an additional 194,835 shares during the period. Isthmus Partners LLC grew its holdings in OmniAb by 37.2% during the second quarter. Isthmus Partners LLC now owns 528,385 shares of the company's stock valued at $1,981,000 after purchasing an additional 143,387 shares during the period. Squarepoint Ops LLC bought a new stake in OmniAb during the second quarter valued at about $449,000. Finally, Janus Henderson Group PLC increased its position in OmniAb by 1.0% in the first quarter. Janus Henderson Group PLC now owns 7,859,438 shares of the company's stock worth $42,598,000 after buying an additional 81,541 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company's stock.

OmniAb Stock Performance

Shares of OABI stock traded up $0.09 on Friday, hitting $4.18. The stock had a trading volume of 297,064 shares, compared to its average volume of 501,471. OmniAb, Inc. has a one year low of $3.56 and a one year high of $6.72. The business has a 50 day moving average price of $4.15 and a 200 day moving average price of $4.30.

OmniAb (NASDAQ:OABI - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.05. The company had revenue of $7.61 million during the quarter, compared to the consensus estimate of $6.52 million. OmniAb had a negative net margin of 287.29% and a negative return on equity of 20.21%. During the same period last year, the firm earned ($0.15) earnings per share. As a group, equities research analysts forecast that OmniAb, Inc. will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on OABI. HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of OmniAb in a report on Monday, August 12th. Royal Bank of Canada restated an "outperform" rating and set a $7.00 target price on shares of OmniAb in a research report on Friday, August 16th. Finally, Benchmark reiterated a "buy" rating and issued a $8.00 price target on shares of OmniAb in a report on Monday, August 19th.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.